Citations

Clear

13603 citation(s) found for "_, _".

Why Consider Aspirin for the Treatment of Vestibular Schwannoma? A Brief Review and Randomized, Double‐Blind, Placebo‐Controlled Study Proposal
Welling, D. Bradley , Neff, Brian A., Telischi, Fred F. , Patel, Neil , Stanković, Konstantina M.

Mayo Clinic

Laryngoscope Investigative Otolaryngology | April 2, 2025 | Volume: 10 | Issue: 2 | Pages: No page available

10.1002/lio2.70121 | PMID 40171318 Get It

ABSTRACTObjectiveThe primary objective of this study is to review the evidence for aspirin use to prevent the growth of vestibular schwannomas (VS) and to propose a prospective trial to determine the progression‐free survival of VS patients after up to 42 months of treatment with aspirin. Secondary study objectives are to determine the effect of aspirin on VS growth, hearing function, serum biomarker levels, and the quality of life, as well as to determine the tolerability of aspirin treatment and whether serum biomarker and salicylate levels predict the response to aspirin.Study DesignLiterature review.SettingSix academic and private medical centers.MethodsReview of recent English literature regarding prophylactic aspirin use for VS.ResultsThe retrospective reviews on the utility of aspirin to prevent VS growth are inconclusive. Eighty‐four patients have been enrolled in a prospective double‐blinded, placebo‐controlled trial thus far to determine the effect of aspirin on VS.ConclusionsCompletion of a robust study design is necessary. The current aspirin dose has been well tolerated, with minimal adverse events to date.Level of EvidenceReview of retrospective studies: Level 4; Proposed randomized, placebo‐controlled, double‐blinded clinical trial: Level 2.
Temporal Hindsight, Clinical Foresight: Longitudinal Lymphoma Analysis at PET/CT
Khosravi, Bardia , Gichoya, Judy Wawira , Gichoya, Judy W. , Khosravi, Bardia

Mayo Clinic

Radiology: Artificial Intelligence | April 2, 2025 | Volume: 7 | Issue: 3 | Pages: No page available

10.1148/ryai.250149 | PMID 40172324 Get It

Refining, not redefining: a reaffirmation of chronic painful CIPN prevalence estimates
D’Souza, Ryan S. , Her, Yeng F , Hussain, Nasir , D'Souza, Ryan S

Mayo Clinic

Regional Anesthesia & Pain Medicine | April 1, 2025 | Volume: No volume available | Issue: No issue available | Pages: rapm-2025-106633

10.1136/rapm-2025-106633 | PMID 40169360 Get It

Treat-to-target of endoscopic remission in patients with inflammatory bowel disease in symptomatic remission on advanced therapies (QUOTIENT): rationale, design and protocol for an open-label, multicentre, pragmatic, randomised controlled trial
Singh, Siddharth , Nguyen, J. , Fudman, David , Gerich, Mark E. , Hudesman, David , McConnell, Ryan , Flynn, Ann D. , Hwang, Caroline, Sprung, Brandon, Gaidos, Jill , Mattar, Mark , Metwally, Mark, Ali, Tauseef , Narula, Neeraj, Rosenfeld, Greg , Cross, Raymond, Gaytán, Josep María, Gurrola, Emily-Sophinie, Patel, Sagar , Melmed, Gil , Weaver, Sarah , Power, Sydney, Jairath, Vipul , Hou, Jason K. , Jairath, Vipul , Jairath, Vipul , Fudman, David I , Hudesman, David , Flynn, Ann D , Sprung, Brandon , Gaidos, Jill K J , Ali, Tauseef , Hoentjen, Frank , Bessissow, Talat , Patel, Sagar , Siegel, Corey A , Zou, Guangyong , Jairath, Vipul , Jairath, V , Jairath, V , Melmed, Gil Y , Nguyen, Jasmine D, Shah, Shiraz Ali , Lukin, Dana J. , Rubin, David T. , Hashash, Jana G. , Ma, C , Narula, Neeraj , Bessissow, Talat , McCurdy, Jeffrey D , Ananthakrishnan, Ashwin N. , Gurrola, Emily-Sophinie, Power, Sydney , Zou, Guangyong

Mayo Clinic

BMJ Open Gastroenterology | April 1, 2025 | Volume: 12 | Issue: 1 | Pages: e001615

10.1136/bmjgast-2024-001615 | PMID 40164445 Get It

Introduction Targeted immunomodulators (eg, advanced therapies) effectively achieve symptomatic remission in patients with inflammatory bowel disease (IBD). However, ~25%–50% of patients with IBD achieving symptomatic remission with an advanced therapy may have continued endoscopically/radiologically active bowel inflammation, and it is uncertain whether changing alternative advanced therapies in asymptomatic patients with IBD will reduce bowel inflammation and achieve durable deep remission. Methods and analysis The QUality Outcomes Treating IBD to Target (QUOTIENT) study is an open-label, multicentre, pragmatic, randomised, controlled trial that aims to compare the efficacy and safety of switching to an alternative advanced therapy targeting endoscopic/radiological remission (treat-to-target) versus continuing the initial, or index, advanced therapy, in asymptomatic patients with IBD with moderate-to-severe endoscopic/radiological bowel inflammation. Enrolment is planned for ~250 participants in Canada/USA, randomised 1:1 to switching to alternative advanced therapy or continuing index advanced therapy, and then followed 104 weeks within routine clinical practice. Patient-reported outcomes measure efficacy and quality of life/treatment burden/safety. Primary endpoint is the time from randomisation to treatment failure. Ethics and dissemination The study is conducted in compliance with the protocol, ICH Good Clinical Practice, applicable regulatory requirements and appropriate review boards/independent ethics committees (approval numbers: Pro00077486; Pro00061437; STUDY00002062; 22-004171; i22-01269; IRB22-0890; IRB_00154397; 2000032384; SHIRB#2022.095-2; STUDY00007146; MMC#2024-18; REB#125290; 17784; Pro00142214; 20240660-01H), with documented written informed consent. Findings will be disseminated through peer-reviewed journals, scientific presentations, and publicly available Patient-Centered Outcomes Research Institute (PCORI) websites, including lay summaries. The Crohn’s & Colitis Foundation Education, Support, and Advocacy Department, and our patient advocacy stakeholder, will develop educational and marketing resources to communicate findings to a broad audience (>250 000 patients/caregivers/healthcare professionals). Trial registration number NCT05230173 .
A Qualitative Study of the Effects of Opioids on Chronic Pain, Function, and Cognition in Community-Dwelling Older Adults
Warner, Nafisseh S. , Finnie, Dawn M., Smith, Jamie, Verdoorn, Brandon P. , Tung, Ericka E. , Griffin, Joan M. , Griffin, Joan M , Warner, Nafisseh , Smith, Jamie L , Warner, David O. , Mielke, Michelle M.

Mayo Clinic

Journal of Applied Gerontology | April 1, 2025 | Volume: 44 | Issue: 12 | Pages: 1939-1949

10.1177/07334648251326347 | PMID 40167777 Get It

Chronic pain is common with aging. Yet, little is known about the attitudes, beliefs, and experiences of older adults with chronic pain regarding opioids, particularly in regard to effects on daily functioning and cognition. This qualitative analysis employed semi-structured interviews in 25 community-dwelling older adults with chronic pain and current or recent prescription opioid use. Interviews focused on perceptions, beliefs, and experiences of living with chronic pain, use of prescription opioids, and the impact of opioids on pain control, cognition, and daily function. Older adults display adaptability and acceptance in living with chronic pain, desire person-centered pain care, approach the risks-benefits of opioids with regards to cognition differently, and perceive stigma as a barrier to effective partnership with clinicians.
Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data, and Outcomes
Katragadda, Silpita , Yetmar, Zachary A. , Chesdachai, Supavit , Fida, Madiha , Pritt, Bobbi S. , Saleh, Omar Abu , Ranganath, Nischal , Challener, Douglas , Abu Saleh, Omar M, Ranganath, Nischal , Yetmar, Zachary A , Fida, Madiha , Pritt, Bobbi S , Chesdachai, Supavit , Challener, Douglas W.

Mayo Clinic

Clinical Infectious Diseases | April 1, 2025 | Volume: 82 | Issue: 3 | Pages: 539-547

10.1093/cid/ciaf171 | PMID 40176262 Get It

Abstract Background There is a lack of comprehensive, large cohort studies investigating the predictors for severity and hospitalization in human granulocytic anaplasmosis (HGA). Methods We conducted a retrospective cohort study including all cases of HGA identified by positive blood Anaplasma polymerase chain reaction (PCR) at the Mayo Clinic Laboratory, Rochester between 2011 and 2021. Multivariable logistic regression was performed to evaluate risk factors associated with hospitalization. Results A total of 465 cases were identified. Of those, 67% (n = 312) were managed in the outpatient setting. Hospitalized patients (n = 153, 33%) were more likely to be older (median age of 71 vs 61; P ≤ .001) and immunocompromised (17% vs 7%; P ≤ .001). The triad of leukopenia, thrombocytopenia, and transaminitis was observed in 24% of the cases, but was associated with risk of hospitalization (odds ratio [OR] 1.78, 95% confidence interval [CI]: 1.05–3.03; P ≤ .033). The presence of a coinfection did not impact mortality or hospitalization. Conclusions The risk factors for hospitalization in patients with HGA include altered mental status, higher absolute neutrophil count (ANC), advanced age, comorbidities, and immunosuppression. The classic hematological and biochemical profile may be absent in the majority of cases. Co-testing may be of higher benefit in select cases.
The diagnostic role of pharmacological provocation testing in cardiac electrophysiology: a clinical consensus statement of the European Heart Rhythm Association and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC, t
Behr, Elijah R. , Winkel, Bo Gregers , Ensam, Bode , Alfie, Alberto , Arbelo, Elena , Berry, Colin , Conte, Giulio , Crotti, Lia , Corcia, M. Cecilia Gonzalez , Kaski, Juan Carlos , Schulze‐Bahr, Eric , Wilde, Arthur A.M. , Tfelt‐Hansen, Jacob , Wolpert, Christian, Cuesta, Alejandro, Damman, Peter, Dobrev, Dobromir, Drago, Fabrizio, Haugaa, Kristina, Krahn, Andrew, Krause, Ulrich, Lambiase, Pier D, Napolitano, Carlo, Odening, Katja E, Shimizu, Wataru, Veltmann, Christian, Lambiase, Pier D. , Odening, Katja E. , Cerrone, Marina , Conte, Giulio , Crotti, Lia , Kaski, Juan Carlos , Nademanee, Koonlawee , Postema, Pieter G , Priori, Silvia , Probst, Vincent , Sarquella-Brugada, Georgia , Schulze-Bahr, Eric , Tadros, Rafik , Wilde, Arthur A M , Tfelt-Hansen, Jacob , Behr, Elijah Raphael , Lambiase, Pier D , Odening, Katja E , Arbelo, Elena , Berry, Colin , Cerrone, Marina , Nademanee, Koonlawee , Postema, Pieter G. , Priori, Silvia G. , Tadros, Rafik , Wolpert, Christian, Cuesta, Alejandro, Damman, Peter, Dobrev, Dobromir, Drago, Fabrizio, Haugaa, Kristina, Krahn, Andrew, Krause, Ulrich, Napolitano, Carlo, Shimizu, Wataru, Veltmann, Christian

Mayo Clinic

Europace | April 1, 2025 | Volume: 27 | Issue: 4 | Pages: No page available

10.1093/europace/euaf067 | PMID 40165484 Get It

Abstract The pharmacological provocation test is a pivotal tool in cardiac electrophysiology for the diagnosis of potential causes of sudden cardiac death, sudden cardiac arrest (SCA), arrhythmias, symptoms, or ECG abnormalities. The 2022 European Society of Cardiology Guidelines for the Treatment of Ventricular Arrhythmias and Prevention of Sudden Cardiac Death offered guidance on provocation testing but did not describe the indications and requirements in depth. This clinical consensus statement, led by the European Heart Rhythm Association and approved by major international stakeholders, aims to advise the general cardiologist and the arrhythmia expert who to test and when, where, and how to do it. The statement focuses on current practice for the diagnosis of subclinical arrhythmia syndromes and the causes of SCA, building upon the recommendations of the Guidelines. We address the sodium channel blocker provocation test for patients suspected of Brugada syndrome as well as the use of epinephrine, isoproterenol, adenosine, ergonovine, and acetylcholine.
Prospective Symptom Changes in Sporadic Vestibular Schwannoma: A Comparison of Observation, Microsurgery, and Radiosurgery
Khandalavala, Karl R. , Lohse, Christine M. , Tombers, Nicole M. , Link, Michael J., Carlson, Matthew L. , Link, Michael J.

Mayo Clinic

Otology & Neurotology | April 1, 2025 | Volume: 46 | Issue: 5 | Pages: 581-586

10.1097/mao.0000000000004495 | PMID 40164982 Get It

Objective To compare differences in sporadic vestibular schwannoma (VS)–associated patient-reported symptom scores among patients receiving observation, microsurgery, or radiosurgery. Study Design Prospective longitudinal survey. Setting Tertiary referral center and the national Acoustic Neuroma Association. Patients Adults with sporadic VS. Intervention Observation, microsurgery, or radiosurgery. Main Outcome Measure Baseline and follow-up surveys on patient-reported severity of tinnitus, dizziness/imbalance, and headaches scored on a 10-point numeric scale, with higher scores indicating more severe symptoms; changes of 2 or more points from baseline were considered clinically important. Results A total of 455 patients were eligible for study with a mean (SD) follow-up of 4.5 (2.4) years, including 122 (27%) managed with observation, 226 (50%) undergoing microsurgery, and 107 (23%) undergoing radiosurgery. Changes in tinnitus severity scores differed significantly among management groups (p = 0.006), with severity scores increasing significantly in the radiosurgery (+0.8, p = 0.005) group but not in the observation (+0.2, p = 0.5) or microsurgery (−0.2, p = 0.18) groups. The changes in dizziness/imbalance and headache severity scores did not differ significantly among management groups. When comparing clinically important improvements (decrease of 2 or more points), the microsurgery and observation cohorts had a greater proportion of patients experiencing a clinically important improvement in tinnitus compared with the radiosurgery cohort; no other clinically important changes were significantly different among management groups. Conclusions In this prospective study of 455 patients comparing patient-reported symptoms after VS management, radiosurgery was associated with worsening tinnitus severity scores overall and resulted in fewer patients reporting clinically important improvements in tinnitus compared with observation and microsurgery. As there was substantial variability in the effect of management modality on changes in symptom severity scores, possible treatment effects on subjective symptoms, including tinnitus, dizziness/imbalance, and headache, should not be used in isolation to inform clinical decision-making for management of sporadic VS.
Frequency and outcomes of BRAF alterations identified by liquid biopsy in metastatic, non-colorectal gastrointestinal cancers
Mahipal, Amit , Mahipal, Amit , Bucheit, Leslie , Zhang, Nicole J. , Barnett, Reagan M. , Storandt, Michael H. , Chakrabarti, Sakti

Mayo Clinic

The Oncologist | March 31, 2025 | Volume: 30 | Issue: 3 | Pages: No page available

10.1093/oncolo/oyaf044 | PMID 40163685 Get It

Abstract Background Impact of BRAF V600E mutations (BRAFV600E), a poor prognostic factor in metastatic colorectal cancer, is lacking in non-CRC gastrointestinal (GI) cancers including pancreatic (PDAC), gastric/gastroesophageal (GEA), hepatocellular carcinoma (HCC), and cholangiocarcinoma (CCA). Due to tumor-agnostic approvals for patients with BRAFV600E, understanding the frequency and impact of BRAF alterations across non-CRC GI cancers is essential for clinical decision-making. Methods Patients with PDAC, GEA, HCC, or CCA who had cell-free DNA detected on Guardant360 (Guardant Health) from 2020 to 2023 were queried. Prevalence of characterized BRAF genomic alterations (GA) was calculated; GAs were grouped by class (Class I/II/III). The Chi-squared test assessed differences between cancer types. A subset of patients had outcomes analysis using GuardantINFORM, a real-world clinicogenomic database, to derive real-world overall survival (rwOS). Results Of 32 480 included patients, BRAF GAs were identified in 4.4%; 19% were BRAFV600E (0.81% prevalence overall). CCA had the highest rate of BRAF GAs and BRAFV600E (P < .01); HCC and GEA had the highest rates of BRAF class II/III alterations. There were no significant differences in rwOS by alteration class or cancer type; numeric differences were observed by alteration class. Few patients were treated with BRAF inhibitors (2.2%). Prevalence of co-occurring alterations was unique by cancer type. Conclusions Frequency of BRAF GAs, including BRAFV600E, in non-CRC GI cancers detected by liquid biopsy is similar to tissue-based rates and can be reliably used to assess BRAF status. BRAF GAs have mixed prognostic implications on survival for patients with non-CRC GI malignancies that warrant further exploration.
In critical illness with suspected sepsis, PCT-guided antibiotics vs. standard care reduced antibiotic duration and was noninferior for 28-d mortality
McHugh, Jack , O'Horo, Jack, McHugh, Jack , O’Horo, John C.

Mayo Clinic

Annals of Internal Medicine | March 31, 2025 | Volume: 178 | Issue: 4 | Pages: JC40

10.7326/annals-25-00906-jc | PMID 40163882 Get It